X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (62) 62
index medicus (51) 51
animals (42) 42
immunology (38) 38
transplantation (33) 33
female (29) 29
antibodies, monoclonal - therapeutic use (28) 28
male (27) 27
t cells (27) 27
immunosuppressive agents - therapeutic use (25) 25
anti-cd25 monoclonal-antibody (23) 23
interleukin-2 receptor alpha subunit - immunology (23) 23
t-lymphocytes, regulatory - immunology (23) 23
mice (22) 22
anti-cd25 (20) 20
adult (19) 19
immunotherapy (19) 19
basiliximab (18) 18
daclizumab (18) 18
middle aged (18) 18
regulatory t-cells (18) 18
oncology (17) 17
immunoglobulin g - therapeutic use (15) 15
anti-cd25 monoclonal antibody (14) 14
monoclonal-antibody (14) 14
surgery (14) 14
antibodies, monoclonal, humanized (13) 13
cancer (13) 13
flow cytometry (13) 13
regulatory t cells (13) 13
foxp3 (12) 12
immunosuppression (12) 12
lymphocytes t (12) 12
mice, inbred c57bl (12) 12
analysis (11) 11
cytokines (11) 11
lymphocytes (11) 11
receptors, interleukin-2 - immunology (11) 11
t-lymphocytes, regulatory - metabolism (11) 11
treatment outcome (11) 11
antibodies, monoclonal - immunology (10) 10
chemical and pharmacologic phenomena (10) 10
hematology (10) 10
induction (10) 10
interleukin-2 (10) 10
interleukin-2 receptor alpha subunit - metabolism (10) 10
kidney transplantation (10) 10
monoclonal antibodies (10) 10
t-lymphocytes - immunology (10) 10
anti-cd25 antibody (9) 9
antibodies (9) 9
dendritic cells (9) 9
health aspects (9) 9
immune system (9) 9
kidney transplantation - immunology (9) 9
rejection (9) 9
retrospective studies (9) 9
acute rejection (8) 8
antibodies, monoclonal - administration & dosage (8) 8
care and treatment (8) 8
cd25 (8) 8
cd25 antigen (8) 8
graft rejection - prevention & control (8) 8
immunoregulation (8) 8
immunosuppressive agents - administration & dosage (8) 8
interleukin-2 receptor alpha subunit - antagonists & inhibitors (8) 8
prevention (8) 8
trial (8) 8
tumors (8) 8
vaccines (8) 8
aged (7) 7
anti-cd25 treatment (7) 7
antibodies, monoclonal - pharmacology (7) 7
autoimmunity (7) 7
child (7) 7
depletion (7) 7
disease models, animal (7) 7
graft rejection - immunology (7) 7
graft vs host disease - prevention & control (7) 7
hemic and immune systems (7) 7
immunoglobulin g - administration & dosage (7) 7
melanoma (7) 7
mice, inbred balb c (7) 7
multiple sclerosis (7) 7
receptors, interleukin-2 - antagonists & inhibitors (7) 7
recombinant fusion proteins - therapeutic use (7) 7
tacrolimus (7) 7
therapy (7) 7
transplantation, homologous (7) 7
versus-host-disease (7) 7
adolescent (6) 6
antibodies, monoclonal, humanized - therapeutic use (6) 6
anti‐cd25 monoclonal antibody (6) 6
article (6) 6
bone-marrow-transplantation (6) 6
cell biology (6) 6
cell line, tumor (6) 6
clinical neurology (6) 6
clinical trials (6) 6
cutting edge (6) 6
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Biology of Blood and Marrow Transplantation, ISSN 1083-8791, 2012, Volume 18, Issue 4, pp. 523 - 535
T cell depletion prevents graft-versus-host disease (GVHD) but also removes T cell-mediated support of hematopoietic cell engraftment. A chimeric molecule... 
Hematology, Oncology and Palliative Medicine | Bone marrow transplantation | Interleukin-2 | Fusion protein | Caspase-3 | Regulatory T cell | Apoptosis | BONE-MARROW-TRANSPLANTATION | IMMUNE RECONSTITUTION | IMMUNOLOGY | TRANSPLANTATION | REGULATORY-CELLS | INFLAMMATORY-BOWEL-DISEASE | HLA-IDENTICAL SIBLINGS | ANTI-CD25 MONOCLONAL-ANTIBODY | STEM-CELL | HEMATOLOGY | CASPASE ACTIVATION | DONOR CELLS | SOLUBLE FAS LIGAND | Graft vs Host Disease - therapy | Recombinant Fusion Proteins - immunology | Antigens, CD - immunology | Whole-Body Irradiation | Spleen - immunology | Recombinant Fusion Proteins - pharmacology | Antigens, CD - biosynthesis | Apoptosis - drug effects | Caspase 3 - immunology | Adoptive Transfer | Lymphocyte Depletion | Molecular Targeted Therapy | Graft vs Host Disease - immunology | T-Lymphocytes - transplantation | T-Lymphocytes, Regulatory - immunology | Bone Marrow Transplantation - immunology | Interleukin-2 - immunology | T-Lymphocytes - drug effects | Caspase 3 - genetics | Severity of Illness Index | Cells, Cultured | Spleen - cytology | Mice, Inbred Strains | Transplantation, Isogeneic | Interleukin-2 - genetics | T-Lymphocytes, Regulatory - drug effects | Animals | Apoptosis - immunology | Recombinant Fusion Proteins - genetics | Graft vs Host Disease - prevention & control | T-Lymphocytes - immunology | Mice | Lymphocytes | Analysis | Immunotherapy | Bone marrow | Transplantation | Universities and colleges | T cells | Mitogens
Journal Article
International Journal of Radiation Oncology, Biology, Physics, ISSN 0360-3016, 2011, Volume 81, Issue 4, pp. 1128 - 1135
Purpose Immunotherapy could be a useful adjunct to standard cytotoxic therapies such as radiation in patients with micrometastatic disease, although successful... 
Radiology | Hematology, Oncology and Palliative Medicine | Anti-CD25 therapy | Radiation therapy | T regulatory cells | Transgenic adenocarcinoma of mouse prostate | TUMOR | ADENOSINE | PERIPHERAL-BLOOD | RESPONSES | CANCER-PATIENTS | THERAPY | ONCOLOGY | TRANSCRIPTION FACTOR FOXP3 | PROSTATE-CANCER | RADIOTHERAPY | RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING | ANTIGEN | Whole-Body Irradiation | Prostatic Neoplasms - radiotherapy | CD4-Positive T-Lymphocytes - radiation effects | Male | Prostatic Neoplasms - immunology | T-Lymphocytes, Regulatory - immunology | T-Lymphocytes, Regulatory - radiation effects | Immunotherapy | Female | Scattering, Radiation | Adenocarcinoma - radiotherapy | Radiation Tolerance - immunology | Adenocarcinoma - immunology | Mice, Inbred C57BL | Biomarkers - analysis | Hindlimb - radiation effects | Mice, Transgenic | Spleen - cytology | Lymph Nodes - cytology | Animals | CD24 Antigen - analysis | Forkhead Transcription Factors - analysis | Cell Line, Tumor | Interleukin-2 Receptor alpha Subunit - analysis | Lymphocyte Count | Mice | Dose-Response Relationship, Radiation | T cells | Radiotherapy | Radiation | PROSTATE | IRRADIATION | PATIENTS | IMMUNOTHERAPY | LEGS | CARCINOMAS | RADIOLOGY AND NUCLEAR MEDICINE | LYMPHOCYTES | anti-CD25 therapy | transgenic adenocarcinoma of the mouse prostate | radiation therapy
Journal Article
British Journal of Haematology, ISSN 0007-1048, 10/2017, Volume 179, Issue 1, pp. 20 - 35
Summary CD25 (also termed IL2RA) forms one component of the high‐affinity heterotrimeric interleukin 2 (IL2) receptor on activated T cells. Its affinity for... 
regulatory T cells | interleukin‐2 receptor | CD25 | anti‐CD25 targeted therapy | CD25‐expressing malignancies | CD25-expressing malignancies | interleukin-2 receptor | anti-CD25 targeted therapy | MONOCLONAL-ANTIBODY TREATMENT | SERUM-SOLUBLE INTERLEUKIN-2-RECEPTOR | FOLLICULAR LYMPHOMA | REGULATORY T-CELLS | IMMUNOTOXIN RFT5-SMPT-DGA | INTERLEUKIN-2-RECEPTOR ALPHA-CHAIN | RETROSPECTIVE ANALYSIS | HEMATOLOGY | C-RECEPTOR POLYMORPHISMS | PHASE-I | HEMATOLOGIC MALIGNANCIES | Interleukin-2 - metabolism | Neoplasms - metabolism | Immunomodulation - drug effects | T-Lymphocytes, Regulatory - metabolism | Interleukin-2 Receptor alpha Subunit - antagonists & inhibitors | Antibodies, Monoclonal - pharmacology | Humans | Receptors, Interleukin-2 - metabolism | Antibodies, Monoclonal - therapeutic use | Molecular Targeted Therapy | Neoplasms - drug therapy | T-Lymphocytes, Regulatory - immunology | Gene Expression Regulation - drug effects | T-Lymphocytes, Regulatory - drug effects | Interleukin-2 Receptor alpha Subunit - genetics | Interleukin-2 Receptor alpha Subunit - metabolism | Neoplasms - genetics | Signal Transduction - drug effects | Neoplasms - immunology | Immunologic Factors - pharmacology | Immunologic Factors - therapeutic use | Interleukin-2 Receptor alpha Subunit - immunology | Biological products | T cells | Stem cells | Cancer | Medical research | Interleukin 2 receptors | Hematology | Immunomodulation | Interleukin | Clinical trials | Lymphocytes T | Modulators | Immunotoxins | Signal transduction | Signaling | Interleukin 2 | Lymphocytes | CD25 antigen | Affinity | Tumors | Immune system | Index Medicus
Journal Article
Current Drug Targets, ISSN 1389-4501, 09/2011, Volume 12, Issue 10, pp. 1433 - 1439
Ulcerative Colitis (UC) is an idiopathic chronic inflammation. Its etiology is still largely unknown. Environmental and genetic factors in combination with the... 
Anti TNF-α | Cytokines | Anti-CD25 | Biologics | Growth factors | PPAR-γ | Anti adhesion-molecules | Ulcerative colitis | MODERATE | biologics | growth factors | anti-CD25 | PHASE-II | MONOCLONAL-ANTIBODY | EXACERBATION | PPAR-gamma | TRIAL | PATHOGENESIS | INFLAMMATORY-BOWEL-DISEASE | ALICAFORSEN | anti TNF-alpha | DOUBLE-BLIND | PHARMACOLOGY & PHARMACY | cytokines | anti adhesion-molecules | VISILIZUMAB
Journal Article
Journal of Clinical Immunology, ISSN 0271-9142, 1/2007, Volume 27, Issue 1, pp. 1 - 18
Twenty-five years ago, we reported the production of the monoclonal antibody, anti-Tac that identifies the IL-2 receptor alpha subunit and blocks the... 
Medical Microbiology | Anti-Tac | Biomedicine | Immunology | adult T-cell leukemia | IL-2 receptor | Internal Medicine | Infectious Diseases | monoclonal antibody | daclizumab | Daclizumab | Adult T-cell leukemia | Monoclonal antibody | LIVER-TRANSPLANT RECIPIENTS | NATURAL-KILLER-CELLS | anti-Tac | HUMAN INTERLEUKIN-2 RECEPTOR | T-CELL LEUKEMIA | RENAL-TRANSPLANTATION | IMMUNOLOGY | IN-VIVO BLOCKADE | MURINE MODEL | ANTI-CD25 MONOCLONAL-ANTIBODY | NF-KAPPA-B | Paraparesis, Tropical Spastic - drug therapy | Receptors, Interleukin-2 - antagonists & inhibitors | Interleukin-2 Receptor alpha Subunit - antagonists & inhibitors | Humans | Immunosuppressive Agents - therapeutic use | Antibodies, Monoclonal - therapeutic use | Leukemia - metabolism | Receptors, Interleukin-2 - drug effects | Interleukin-2 - antagonists & inhibitors | Antibodies, Monoclonal, Humanized | Interleukin-2 - immunology | Leukemia-Lymphoma, Adult T-Cell - drug therapy | Immunoglobulin G - immunology | Immunoglobulin G - pharmacology | Binding, Competitive - immunology | Antibodies, Monoclonal - immunology | Autoimmune Diseases - drug therapy | Interleukin-2 Receptor alpha Subunit - immunology | Uveitis - drug therapy | Antibodies, Monoclonal - pharmacology | Graft Rejection - prevention & control | Immunoglobulin G - therapeutic use | Leukemia - drug therapy | Receptors, Interleukin-2 - immunology | Animals | Mice | Graft Rejection - immunology | Prevention | Care and treatment | Leukemia | Physiological aspects | Lymphomas | Autoimmune diseases | Drug therapy | Cancer
Journal Article
Leukemia Research, ISSN 0145-2126, 2011, Volume 36, Issue 7, pp. 857 - 861
Abstract Adult T-cell leukaemia lymphoma (ATLL) is an aggressive T-cell malignancy caused by the human T-lymphotropic virus type-1 (HTLV-1) and is associated... 
Hematology, Oncology and Palliative Medicine | Anti-CD25 antibodies | Adult T-cell leukaemia lymphoma | HTLV-1 | LEUKEMIA-LYMPHOMA | PROGNOSTIC FACTORS | INTERLEUKIN-2-RECEPTOR | ANTI-TAC | CHEMOTHERAPY | MURINE MODEL | INTERFERON-ALPHA | ONCOLOGY | ZIDOVUDINE | VIRUS TYPE-I | LEUKEMIA/LYMPHOMA | HEMATOLOGY | Doxorubicin - therapeutic use | Cyclophosphamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Humans | Immunosuppressive Agents - therapeutic use | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Cyclophosphamide - adverse effects | Cyclophosphamide - therapeutic use | Antibodies, Monoclonal, Humanized - administration & dosage | Leukemia-Lymphoma, Adult T-Cell - drug therapy | Vincristine - administration & dosage | Adult | Female | Immunosuppressive Agents - administration & dosage | Leukemia-Lymphoma, Adult T-Cell - therapy | Doxorubicin - administration & dosage | Antibodies, Monoclonal, Humanized - adverse effects | Prednisone - administration & dosage | Antibodies, Monoclonal, Humanized - therapeutic use | Prednisone - adverse effects | Leukemia-Lymphoma, Adult T-Cell - mortality | Immunoglobulin G - therapeutic use | Treatment Outcome | Combined Modality Therapy | Immunoglobulin G - administration & dosage | Immunoglobulin G - adverse effects | Immunotherapy - adverse effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Survival Analysis | Vincristine - therapeutic use | Vincristine - adverse effects | Immunosuppressive Agents - adverse effects | Aged | Doxorubicin - adverse effects | Prednisone - therapeutic use | Viral antibodies | Care and treatment | Chemotherapy | Leukemia | Monoclonal antibodies | Antibodies | Skin | Lymphomas | Drug therapy, Combination | T cells | Cancer | Tumors | Interleukin 2 receptors | Prognosis | Clinical trials | Lymphocytes T | Malignancy | Lymphoma | Survival | Lymphadenopathy | CD25 antigen | Skin diseases | Lymphocytosis
Journal Article
Journal Article
Journal Article
Biology of Blood and Marrow Transplantation, ISSN 1083-8791, 2012, Volume 18, Issue 3, pp. 466 - 472
Patients suffering from high-risk myelodysplastic syndrome (MDS) or acute myelogenous leukemia (AML) secondary to MDS (sAML) are characterized by poor response... 
Hematology, Oncology and Palliative Medicine | Graft-versus-host disease | Interleukin-2 receptor antagonists | Anti-CD25 monoclonal antibody | Unrelated donor | Peripheral blood stem cell transplantation | TOTAL-BODY IRRADIATION | LONG-TERM | INDUCTION CHEMOTHERAPY | BONE-MARROW-TRANSPLANTATION | ACUTE MYELOGENOUS LEUKEMIA | IMMUNOLOGY | FLUDARABINE | COMORBIDITY | TRANSPLANTATION | THERAPY | HLA-IDENTICAL SIBLINGS | HOST-DISEASE | HEMATOLOGY | Cyclophosphamide - administration & dosage | Humans | Middle Aged | Male | Busulfan - administration & dosage | Transplantation, Homologous | Myelodysplastic Syndromes - therapy | Hematopoietic Stem Cell Transplantation - adverse effects | Leukemia, Myeloid, Acute - drug therapy | Adult | Female | Leukemia, Myeloid, Acute - surgery | Transplantation Conditioning - adverse effects | Unrelated Donors | Transplantation Conditioning - methods | Graft vs Host Disease - etiology | Myelodysplastic Syndromes - surgery | Leukemia, Myeloid, Acute - therapy | Myelodysplastic Syndromes - drug therapy | Amsacrine - administration & dosage | Vidarabine - analogs & derivatives | Cytarabine - administration & dosage | Disease-Free Survival | Melphalan - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Graft vs Host Disease - prevention & control | Aged | Vidarabine - administration & dosage | Hematopoietic Stem Cell Transplantation - methods | Usage | Chemotherapy | Tacrolimus | Stem cells | Dosage and administration | Transplantation | Mycophenolate mofetil | Hematopoietic stem cells | Cancer | Index Medicus
Journal Article
Lancet Neurology, The, ISSN 1474-4422, 2010, Volume 9, Issue 4, pp. 381 - 390
Summary Background Daclizumab, a humanised monoclonal antibody, reduced multiple sclerosis disease activity in previous non-randomised studies. We aimed to... 
Neurology | NATURAL-KILLER-CELLS | IN-VITRO | ANTI-CD25 ANTIBODY DACLIZUMAB | CD56(BRIGHT) | BLOCKADE | T-CELLS | CLINICAL NEUROLOGY | T-Lymphocytes - physiology | Humans | Immunosuppressive Agents - therapeutic use | Middle Aged | Antibodies, Monoclonal - adverse effects | Magnetic Resonance Imaging - methods | Antibodies, Monoclonal - therapeutic use | Male | Interferon-beta - therapeutic use | Young Adult | Antibodies, Monoclonal, Humanized | Lymphocytes - physiology | Interferon-beta - adverse effects | T-Lymphocytes - drug effects | Adult | Female | Multiple Sclerosis, Chronic Progressive - drug therapy | Immunosuppressive Agents - administration & dosage | Interferon-beta - administration & dosage | Multiple Sclerosis, Relapsing-Remitting - pathology | CD56 Antigen - metabolism | Multiple Sclerosis, Chronic Progressive - physiopathology | Double-Blind Method | Multiple Sclerosis, Relapsing-Remitting - drug therapy | Immunologic Factors - administration & dosage | Immunoglobulin G - therapeutic use | Multiple Sclerosis, Chronic Progressive - pathology | Treatment Outcome | Multiple Sclerosis, Relapsing-Remitting - physiopathology | Immunoglobulin G - administration & dosage | Immunoglobulin G - adverse effects | Brain - drug effects | Antibodies, Monoclonal - administration & dosage | Lymphocytes - drug effects | Adolescent | Brain - pathology | Immunosuppressive Agents - adverse effects | Cell Proliferation - drug effects | Immunologic Factors - adverse effects | Immunologic Factors - therapeutic use | Clinical trials | Multiple sclerosis | Biological response modifiers | Consulting services | Interferon beta
Journal Article